共 50 条
- [31] Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Lakshman, ArjunAbeykoon, Jithma P.Kumar, ShajiRajkumar, S. VincentKourelis, TaxiarchisBuadi, FrancisDingli, DavidLacy, MarthaGonsalves, Wilson I.Dispenzieri, AngelaKyle, Robert A.Lin, YiGo, Ronald S.Warsame, Rahma M.Hayman, Suzanne R.Russell, StephenLeung, NelsonGertz, Morie A.Kapoor, Prashant
- [32] Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysisEUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (05) : 815 - 823LeBlanc, RichardMian, HiraReece, DonnaSu, JiandongMasih-Khan, EstherChu, MichaelJimenez-Zepeda, VictorSebag, MichaelSong, KevinLouzada, MarthaKotb, RamiVisram, AlissaWhite, DarrellStakiw, JulieReiman, AntonyAslam, MuhammadBergstrom, DebraKaedbey, RayanGul, EnginVenner, Christopher
- [33] Real-World Analysis of Treatment Patterns and the Effectiveness and Safety Profile of Daratumumab-Based Regimens in Chinese Patients with Newly Diagnosed or Relapsed/Refractory Multiple MyelomaBLOOD, 2023, 142Wang, LuqunYang, WeiWang, YafeiNiu, TingFu, RongZhong, YupingQian, WenbinDing, KaiyangSun, KaiLiu, HongFang, BaijunLiu, HuiLi, YanhuiYang, YishenZhuo, JianminChen, XiCui, CanchanLu, Jin
- [34] Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesHAEMATOLOGICA, 2020, 105 (02) : 468 - 477Mateos, Maria-VictoriaSpencer, AndrewNooka, Ajay K.Pour, LudekWeisel, KatjaCavo, MicheleLaubach, Jacob P.Cook, GordonIida, ShinsukeBenboubker, LotfiUsmani, Saad Z.Yoon, Sung-SooBahlis, Nizar J.Chiu, ChristopherUkropec, JonSchecter, Jordan M.Qin, XiangO'Rourke, LisaDimopoulos, Meletios A.
- [35] Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaBLOOD, 2019, 134 (08) : 668 - 677Usmani, Saad Z.Nahi, HarethMateos, Maria-Victoriavan de Donk, Niels W. C. J.Chari, AjaiKaufman, Jonathan L.Moreau, PhilippeOriol, AlbertPlesner, TorbenBenboubker, LotfiHellemans, PeterMasterson, TaraClemens, Pamela L.Luo, ManLiu, KevinSan-Miguel, Jesus
- [36] Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple MyelomaDrugs, 2018, 78 : 397 - 397Hannah A. Blair
- [38] In Vitro Model to Predict Response to Daratumumab Therapy in Relapsed/Refractory Multiple MyelomaBLOOD, 2021, 138Van Nieuwenhuijzen, NielsCuenca, MartaAbbink, LeonieLammers, ElineJak, MargotPeperzak, VictorMinnema, Monique C.
- [39] Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case ReportCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (01): : E21 - E24Mina, RobertoBonello, FrancescaGay, FrancescaZamagni, ElenaBoccadoro, Mario
- [40] Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple MyelomaHEMASPHERE, 2022, 6 (10): : E786Sonneveld, PieterZweegman, SonjaCavo, MicheleNasserinejad, KazemBroijl, AnnemiekTroia, RosellaPour, LudekCroockewit, SandraCorradini, PaoloPatriarca, FrancescaWu, KalungDroogendijk, JolandaBos, GerardHajek, RomanTeresa Petrucci, MariaYpma, PaulaZojer, NicholasMinnema, Monique C.Boccadoro, Mario